Navigation Links
World Think Tank on Type 1 Diabetes Meets in Miami
Date:11/13/2007

Panel of experts to present latest science and findings via MEDIA

TELECONFERENCE

BETHESDA, Md., Nov. 13 /PRNewswire/ --

WHAT: On World Diabetes Day, November 14, leaders in type 1 diabetes

research will present their findings to the media via

teleconference. These scientists represent two international groups

of type 1 diabetes researchers meeting in Miami during the week of

November 14 to share their latest findings and plan future

research.

WHEN: November 14, 2007, 12:00 - 1:30 p.m. (EST)

Four experts will make 15-minute presentations, followed by a 30-

minute Q&A.

WHY: This media teleconference presents an outstanding opportunity for

you to get an update on exciting type 1 diabetes research and

advances, as you put together stories for your readers during

American Diabetes Month in November.

-- Type 1 diabetes is increasing every year, reaching epidemic

proportions in some countries, with the greatest increase in

children under age 5. In response to this phenomenon, diabetes

researchers across the globe have been working to advance the

study, prevention and treatment of type 1 diabetes. As a result,

the way we detect and treat diabetes is dramatically changing. A

simple blood test can now identify the autoantibodies for type 1

diabetes up to 10 years before diagnosis.

-- If diabetes can be delayed, even for a few years, those at risk may

be able to postpone the difficult challenges of controlling their

glucose levels and the development of serious complications. The

serious complications of diabetes include heart disease, stroke,

blindness, kidney damage and lower-limb amputations.

PANEL TOPICS & PRESENTERS:

Advances in the Prevention and Reversal of Type 1 Diabetes

Jay Skyler, MD, MACP, University of Miami

Chairman of Type 1 Diabetes TrialNet and Professor at the

internationally renowned University of Miami's Diabetes Metabolic

Unit, Dr. Skyler will give an overview of the current advances and

planned research efforts toward finding ways to prevent and reverse

type 1 diabetes.

Nasal Insulin and Prevention of Type 1 Diabetes

Olli Simell, MD, PhD, University of Turku, Finland

Physician, researcher, and instructor of international stature, Dr.

Simmel will provide an overview of a study testing nasal insulin to

prevent type 1 diabetes in children in Finland. Finland has the

highest incidence of type 1 diabetes in the world.

Adult Stem Cells and Reversal of Type 1 Diabetes

Massimo Trucco, MD, University of Pittsburgh

Hillman Professor of Pediatric Immunology and Division Director of

Immunogenetics at Children's Hospital of Pittsburgh, Dr. Trucco

will provide an update on the use of adult stem cells in the

reversal of type 1 diabetes. He will also talk about the critical

immunologic steps that lead to autoimmunity in type 1 diabetes and

the use of this information to prevent and possibly cure type 1

diabetes.

Umbilical Cord Infusion to Reduce Type 1 Severity and Reset

Immunity

Michael Haller, MD, University of Florida College of Medicine,

Gainesville

Dr. Haller, an innovative and proficient researcher of diabetes in

children, will share how cord blood is being tested to treat type 1

diabetes in children newly diagnosed with type 1 diabetes.

Preliminary results show that it appears to reduce disease

severity, possibly re-setting the immune system and slowing the

destruction of their insulin-producing cells.

ABOUT THE MEETINGS

The Type 1 Diabetes TrialNet Study Group

This group of type 1 diabetes experts will meet November 12-14 to discuss current and planned research around type 1 diabetes. Researchers at more than 150 medical centers in the U.S., Canada, Europe and Australia have joined this global network dedicated to study the prevention, early detection and treatment of type 1 diabetes. These centers are offering free screenings for relatives of people with type 1 diabetes, as well as clinical trials in prevention, early detection and early onset. Type 1 Diabetes TrialNet is supported by the National Institutes of Health (NIH), Juvenile Diabetes Research Foundation International, and the American Diabetes Association. To learn more about Type 1 Diabetes TrialNet, visit http://www.DiabetesTrialNet.org

The 9th International Congress of the Immunology of Diabetes Society (IDS) and American Diabetes Association (ADA) Research Symposium

International researchers will meet November 14-18 to discuss the latest science and theories in type 1 diabetes research. IDS is an international collaboration created to advance research in the etiology, pathogenesis, prevention and cure of type 1 diabetes. A key area of focus is clinical trials to alter the type 1 diabetes disease process, eventually leading to prevention of this disease. ADA's mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

TO REGISTER FOR THE MEDIA TELECONFERENCE:

Please contact:

Sarah Bakka

sbakka@mmgct.com

301.348.1685


'/>"/>
SOURCE TrialNet
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
6. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
7. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
8. PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso
9. Doping technique brings nanomechanical devices into the semiconductor world
10. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
11. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):